123 related articles for article (PubMed ID: 21890881)
1. Paradoxical embolism, stroke and sclerotherapy.
Parsi K
Phlebology; 2012 Jun; 27(4):147-67. PubMed ID: 21890881
[TBL] [Abstract][Full Text] [Related]
2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
3. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
[TBL] [Abstract][Full Text] [Related]
4. Embolic implications of combined risk factors in patients with patent foramen ovale (the CARPE criteria): consideration for primary prevention closure?
Rigatelli G; Dell'Avvocata F; Giordan M; Braggion G; Aggio S; Chinaglia M; Roncon L; Cardaioli P; Chen JP
J Interv Cardiol; 2009 Aug; 22(4):398-403. PubMed ID: 19515082
[TBL] [Abstract][Full Text] [Related]
5. New aspects of paradoxical embolism.
Lehmeyer S; Lindhoff-Last E
Vasa; 2011 Jan; 40(1):31-40. PubMed ID: 21283971
[TBL] [Abstract][Full Text] [Related]
6. Tissue Plasminogen Activator to Treat a Stroke after Foam Sclerotherapy in a Woman with a Patent Foramen Ovale.
Matsuzono K; Arai N; Suzuki M; Kim Y; Ozawa T; Mashiko T; Shimazaki H; Koide R; Matsuura T; Fujimoto S
J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):e110-e112. PubMed ID: 29402614
[TBL] [Abstract][Full Text] [Related]
7. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism.
Spies C; Khandelwal A; Timmemanns I; Kavinsky CJ; Schräder R; Hijazi ZM
Catheter Cardiovasc Interv; 2008 Dec; 72(7):966-70. PubMed ID: 18942060
[TBL] [Abstract][Full Text] [Related]
8. D-dimer for prediction of long-term outcome in cryptogenic stroke patients with patent foramen ovale.
Kim YD; Song D; Nam HS; Lee K; Yoo J; Hong GR; Lee HS; Nam CM; Heo JH
Thromb Haemost; 2015 Aug; 114(3):614-22. PubMed ID: 25994249
[TBL] [Abstract][Full Text] [Related]
9. Predictors of recurrent stroke after percutaneous closure of patent foramen ovale.
Rudolph V; Augustin J; Hofmann T; Hamm CW; Meinertz T; Köster R; Baldus S; Franzen O
EuroIntervention; 2014; 9(12):1418-22. PubMed ID: 24169021
[TBL] [Abstract][Full Text] [Related]
10. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism.
Wahl A; Kunz M; Moschovitis A; Nageh T; Schwerzmann M; Seiler C; Mattle HP; Windecker S; Meier B
Heart; 2008 Mar; 94(3):336-41. PubMed ID: 17639093
[TBL] [Abstract][Full Text] [Related]
11. [Patent foramen ovale and the risk of paradoxical embolization of venous bubbles in divers - cave for foam sclerotization of varicose veins].
Honěk J; Honěk T; Januška J; Sebesta P; Novotný S; Sefc L; Fiedler J; Srámek M; Horváth M; Parobková M
Rozhl Chir; 2012 Jul; 91(7):378-80. PubMed ID: 23078256
[TBL] [Abstract][Full Text] [Related]
12. Recurrent events after percutaneous closure of patent foramen ovale.
Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
[TBL] [Abstract][Full Text] [Related]
13. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
Lehmann R; Fichtlscherer S; Baldauf H; Schächinger V; Auch-Schwelck W; Zeiher AM; Teupe C
J Cardiol; 2014 Aug; 64(2):113-6. PubMed ID: 24480741
[TBL] [Abstract][Full Text] [Related]
14. Cryptogenic stroke and patent foramen ovale.
Thaler DE; Saver JL
Curr Opin Cardiol; 2008 Nov; 23(6):537-44. PubMed ID: 18830067
[TBL] [Abstract][Full Text] [Related]
15. Primary transcatheter patent foramen ovale closure is effective in improving migraine in patients with high-risk anatomic and functional characteristics for paradoxical embolism.
Rigatelli G; Dell'Avvocata F; Ronco F; Cardaioli P; Giordan M; Braggion G; Aggio S; Chinaglia M; Rigatelli G; Chen JP
JACC Cardiovasc Interv; 2010 Mar; 3(3):282-7. PubMed ID: 20298985
[TBL] [Abstract][Full Text] [Related]
16. Stroke following variceal sclerotherapy.
Hanisch F; Müller T; Krivokuca M; Winterholler M
Eur J Med Res; 2004 May; 9(5):282-4. PubMed ID: 15257884
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical embolism through the patent foramen ovale--the elderly is where the money is.
Meier B
Catheter Cardiovasc Interv; 2008 Dec; 72(7):971-2. PubMed ID: 19021283
[No Abstract] [Full Text] [Related]
18. Non-ST-elevation myocardial infarction following foam ultrasound-guided sclerotherapy.
Stephens R; Dunn S
Phlebology; 2014 Aug; 29(7):488-90. PubMed ID: 23563647
[TBL] [Abstract][Full Text] [Related]
19. PFO and paradoxical embolism producing events other than stroke.
Dao CN; Tobis JM
Catheter Cardiovasc Interv; 2011 May; 77(6):903-9. PubMed ID: 21207422
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A
Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
